Overview

Evaluate the Safety and Efficacy of Tafasitamab Combined With Lenalidomide in Patients With Relapsed or Refractory DLBCL

Status:
Recruiting
Trial end date:
2027-04-01
Target enrollment:
Participant gender:
Summary
This is a A Phase II, Single-Arm, Open-Label, Multicentre Study to Evaluate the Safety and Efficacy of Tafasitamab Combined with Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Phase:
Phase 2
Details
Lead Sponsor:
Beijing InnoCare Pharma Tech Co., Ltd.
Treatments:
Lenalidomide